Menu Search
Equities

Pediatrix Medical Group Inc

PDC:BRN

Pediatrix Medical Group Inc

Actions
  • Price (CHF)24.06
  • Today's Change0.00 / 0.00%
  • Shares traded150.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2021.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Pediatrix Medical Group Inc had net income fall from a gain of 66.34m to a loss of 60.41m despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 81.88% to 84.02%.
Gross margin--
Net profit margin-12.65%
Operating margin-11.93%
Return on assets-11.53%
Return on equity-29.85%
Return on investment-13.80%
More ▼

Cash flow in USDView more

In 2023, Pediatrix Medical Group Inc increased its cash reserves by 645.70%, or 63.43m. The company earned 137.33m from its operations for a Cash Flow Margin of 6.88%. In addition the company used 48.18m on investing activities and also paid 25.72m in financing cash flows.
Cash flow per share-2.63
Price/Cash flow per share--
Book value per share8.53
Tangible book value per share-6.05
More ▼

Balance sheet in USDView more

Pediatrix Medical Group Inc has a Debt to Total Capital ratio of 46.11%, a lower figure than the previous year's 64.22%.
Current ratio1.42
Quick ratio--
Total debt/total equity0.8556
Total debt/total capital0.4611
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-387.82
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.